Navigation Links
KV Provides Update on Gestiva(TM) PDUFA Date
Date:10/20/2008

regulatory environment, including regulatory agency and judicial actions and changes in applicable law or regulations; (9) fluctuations in revenues; (10) the difficulty of predicting international regulatory approval, including timing; (11) the difficulty of predicting the pattern of inventory movements by the Company's customers; (12) the impact of competitive response to the Company's sales, marketing and strategic efforts, including the introduction or potential introduction of generic or competing products against products sold by the Company and its subsidiaries; (13) risks that the Company may not ultimately prevail in litigation, including challenges to our intellectual property rights by actual or potential competitors or to our ability to market generic products due to brand company patents and challenges to other companies' introduction or potential introduction of generic or competing products by third parties against products sold by the Company or its subsidiaries including without limitation the litigation and claims referred to in Note 16 of the Notes to the Consolidated Financial Statements in the Company's Form 10-Q for the quarter ended June 30, 2008; (14) actions by the Internal Revenue Service with respect to the Company's stock option grants and accounting practices; (15) the possibility that KV's current estimates of the financial effect of certain previously announced product recalls could prove to be incorrect; (16) whether any product recalls or product introductions results in litigation, agency action or material damages; (17) the possibility that the findings of the Audit Committee inquiry referenced in the Company's Form 10-Q for the quarter ended June 30, 2008, could have a material impact on the Company's financial results; (18) the satisfaction or waiver of the other closing conditions in the Gestiva(TM) acquisition agreement in addition to those noted above; and (19) the risks detailed from time-to-time in the Company's filings with
'/>"/>
SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Young Innovations, Inc. Provides Third Quarter Conference Call Details
2. HealthGrades Expects Third Quarter Revenue of Approximately $10 Million : Full-Year 2008 Ratings and Advisory Revenue to Be $39 Million to $40 Million Company Provides Update on Stock Repurchase Program
3. Cardiome Provides Regulatory Update
4. Enjoy Life Foods Teams with AllergyMoms.com to Ensure Halloween Isn't 'Tricky' for Food-Allergic Kids and Families : Provides tips for being allergy-aware this Halloween
5. Seamobile Provides Foxnews To Mercy Ships
6. Major study of opiate use in childrens hospitals provides simple steps to alleviate harm
7. SecureWorks Provides Solutions to Help with Payment Card Industry (PCI) Data Security Standard (DSS) Version 1.2
8. Quality Healthcare Provides Children Kidney Screening Package
9. Songbird Hearing Provides Revolutionary Alternative for Those Dealing With Hearing Loss
10. PeopleClick, LLC Provides Cutting-Edge Servicing to Parents and Families
11. New Book Provides Brutally Honest, Touching & Funny Essays about Women in Their 40s
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Beverly Hills, CA (PRWEB) May 27, 2015 ... state of the art web portal focussed on keratoconus ... disease. This relentless progressive disease has its onset in the ... quieting down. The cornea or the front clear part of ... withstand the pressure in the eye. It results in poor ...
(Date:5/27/2015)... Arizona (PRWEB) May 27, 2015 Continuing ... mission of healthier patients in the community, SmartPractice® ... Center (formerly John C. Lincoln). SmartPractice Vice President of ... Michelle Shaw presented a $25,000 check to Paulla Miller, ... HonorHealth’s Breast Health & Research Center on April 30. ...
(Date:5/27/2015)... May 27, 2015 Dr. Omar Ibrahimi, ... in Stamford, CT has been selected as part of ... physicians nationwide (and the only physician in Connecticut) to ... allows for the removal of submental fat (double chin). ... recovery time, no surgery and minimal risks. Dr. Ibrahimi ...
(Date:5/27/2015)... CURE® Magazine and the Bladder ... advance research, provide information and support, and raise awareness ... fifth most common type of cancer, which begins when ... out of control. , “CURE Magazine provides guidance ... the cancer experience through digital and print publications, live ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 CompanionDx ... pharmacogenomic and somatic genomic analysis in personalized cancer therapy: ... by the American Society of Clinical Oncology (ASCO) as ... 2 in Chicago. , The molecular and clinical data ... Genome Atlas (TCGA) database. The study reports improved patient ...
Breaking Medicine News(10 mins):Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3
... Million in Compensation and Benefits, MINNEAPOLIS, Dec. 6 ... William McGuire, today agreed to,terms with the UnitedHealth Special ... than $420 million in stock options and other,compensation to ... during,his tenure as CEO of the company, in addition ...
... against colorectal, prostate and oral tumors , , THURSDAY, ... from black raspberries, a fruit beverage and old-fashioned ... to treat or prevent different types of cancer, ... not been considered good treatments for chronic illness, ...
... Inc. (NYSE: WPI ), a leading ... reached a settlement with Novartis,Pharmaceuticals Corporation, Novartis ... and Proterra AG (collectively,"Novartis") on outstanding patent ... (rivastigmine tartrate) capsules., Under the terms ...
... (Nasdaq: NBIX ) announced today that the ... Veralliance Properties for its real estate,assets. Total consideration ... Concurrently with the closing of the transaction, Neurocrine,leased ... term, with renewal,options. Neurocrine also has certain options ...
... EXEL ) announced today that that it will hold ... of Hematology,48th Annual Meeting from 8:00 p.m. to 9:00 p.m. ... webcast and may be accessed in the Event Calendar,page under ... -- Michael Morrissey, PhD, President of Research & Development ...
... University of Pennsylvania School of Medicine and other ... care providers can better their chances of identifying ... the way they ask patients questions., In a ... Internal Medicine, researchers found a number of communication ...
Cached Medicine News:Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 2Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 3Health News:Green Tea, Fruit Extracts Touted as Potential Cancer Fighters 2Health News:Green Tea, Fruit Extracts Touted as Potential Cancer Fighters 3Health News:Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation 2Health News:Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets 2Health News:Reminder: Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction with The American Society Of Hematology 48th Annual Meeting 2Health News:Finding the right words: Provider-patient discussions can help domestic violence victims speak up 2
(Date:5/27/2015)... NEW YORK , May 27, 2015 ... Summary Sepsis patients suffer from a series ... and/or their toxins in the blood or tissues, which ... cellular dysfunction leading to mortality rates near 50% depending ... on the national healthcare systems of the global marketplace, ...
(Date:5/27/2015)... May 27, 2015 The prevalence of cardiovascular ... accelerated aging of population and changes in consumption concept, ... been growing year after year, thereby promoting the development ... in China totaled 454,505 in ... interventional cardiovascular device industry there was worth RMB20.12 billion. ...
(Date:5/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/f6rkcf/north_america ) ... Portable X Ray Devices Market - Growth, Trends ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... for Portable X-Ray Devices is expected to grow ... X-Ray is a form of electromagnetic ...
Breaking Medicine Technology:OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4China Interventional Cardiovascular Device Industry Report, 2014-2017 2China Interventional Cardiovascular Device Industry Report, 2014-2017 3North America Portable X Ray Devices Market Report 2015 - Growth, Trends And Forecasts 2014-2019 2
... Center is,seeking local residents with type 2 diabetes ... study evaluating an investigational,device, the TANTALUS System. Diabetes ... TANTALUS System is an implantable device that delivers ... The primary objective of the,randomized, double-blind controlled study ...
... successfully targets human leukemic stem cells, ATLANTA, ... has today presented data at the American Society,of ... promising,pre-clinical activity of a novel monoclonal antibody, in ... AML is an aggressive cancer of white blood ...
Cached Medicine Technology:Vanderbilt Medical Center Seeks Middle Tennesseans with Type 2 Diabetes Who are Overweight for National Clinical Trial 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 2Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML) 3
Midstream Catch Kits...
... a portable, noninvasive ultrasound instrument that measures ... use, and quickly provides accurate results. In ... the BladderScan® to obtain a precise reading ... supplies the information that caregivers need to ...
... The BladderScan® BVI 6100 is a handheld, ... It is easy to operate, so any ... accurately. To view ultrasound images from exams ... patient records and reimbursement, just log on ...
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
Medicine Products: